title: [Evaluation of bone scintigraphy and (18)F-FDG PET/CT in bone metastases of lung cancer patients].
abstract: OBJECTIVE
  To compare the bone scintigraphy (BS) findings and PET/CT scintigraphy with FDG (FDG PET/CT) in the detection of bone metastases in lung cancer.
  
  
  METHODS
  We studied 32 patients with lung cancer who underwent FDG PET/CT and BS in a period of 15.9±18.6 days. The results of both techniques were compared with the histology, where available, radiological structural techniques and the clinical follow-up. In 30 patients, a definitive diagnosis was reached with the scintigraphic findings. No final diagnosis was obtained in 2 patients.
  
  
  RESULTS
  BS was positive in 25/30 patients (83.3%) and negative in 5 patients. FDG PET/CT was positive in 21/30 patients (70%) and negative in 9. The BS and the FDG PET/CT were positive in 19/30 patients (63.3%) for the detection of bone metastases. In 6/19, both techniques showed the same number of bone lesions. In 10/19, FDG PET/CT showed a greater number of bone metastases than BS. In 3/19 patients, BS showed more lesions than FDG PET/CT and in 2/30 patients (6.6%), the BS was normal and the FDG PET/CT showed bone lesions which were confirmed as metastasis. In 6/30 patients (20%), the FDG PET/CT was negative and the BS was positive. BS and FDG PET/CT scan were normal in 3/30 patients (10%).
  
  
  CONCLUSIONS
  In patients with lung cancer, FDG PET/CT scan detected more metastatic bone lesions than BS. It also identified bone metastasis in negative BS. In our experience, when the BS was positive and the FDG PET/CT scan was negative, the lesions observed were mostly related with degenerative bone conditions and bone fractures. In the clinical practice, the FDG PET/CT and BS have a complementary role for the assessment of bone status in lung cancer patients.
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Cantabria, España. hportilla@gmail.com
authors.forename: H
authors.initials: H
authors.lastname: Portilla-Quattrociocchi
authors.forename: I
authors.initials: I
authors.lastname: Banzo
authors.forename: I
authors.initials: I
authors.lastname: Martínez-Rodríguez
authors.forename: R
authors.initials: R
authors.lastname: Quirce
authors.forename: J
authors.initials: J
authors.lastname: Jiménez-Bonilla
authors.forename: M
authors.initials: M
authors.lastname: de Arcocha Torres
authors.forename: P
authors.initials: P
authors.lastname: Medina-Quiroz
authors.forename: R
authors.initials: R
authors.lastname: del Castillo
authors.forename: A
authors.initials: A
authors.lastname: Rubio-Vassallo
authors.forename: J M
authors.initials: JM
authors.lastname: Carril
mesh_terms: D000368:Aged; D001847:Bone Diseases / Q000000981:diagnostic imaging; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary*; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging* / Q000556:secondary*; D003937:Diagnosis, Differential; D004164:Diphosphonates; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D015902:Gamma Cameras; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015609:Organotechnetium Compounds; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
chemical_list: D004164:Diphosphonates; D005462:Fluorine Radioisotopes; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C033905:technetium Tc 99m 1,1-diphosphonopropane-2,3-dicarboxylic acid; D019788:Fluorodeoxyglucose F18